Skip to main content
Download PDF

Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies

Arthritis Research & Therapy volume 22, Article number: 236 (2020) Cite this article

Abstract

Background

It is not elucidated that there is treatment-related damage in elderly patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV).

Methods

Elderly (≥ 75 years of age) patients were enrolled from two nationwide prospective inception cohort studies. The primary outcome was 12-month treatment-related Vasculitis Damage Index (VDI) score. Secondary outcomes included serious infections within 6 months, total VDI score, remission, and relapse. Patient characteristics and outcomes were compared across three different initial glucocorticoid (GC) dose groups: high-dose, prednisolone (PSL) ≥ 0.8 mg/kg/day; medium-dose, 0.6 ≤ PSL < 0.8 mg/kg/day; and low-dose, PSL < 0.6 mg/kg/day.

Results

Of the 179 eligible patients, the mean age was 80.0 years; 111 (62%) were female. The mean Birmingham Vasculitis Activity Score was 16.1. Myeloperoxidase-ANCA findings were positive in 168 (94%) patients, while proteinase 3-ANCA findings were positive in 11 (6%). The low-dose group was older and had higher serum creatinine levels than the other groups. There were no statistically significant intergroup differences in remission or relapse, whereas serious infection developed more frequently in the high-dose (29 patients [43%]) than the low-dose (13 patients [22%]) or medium-dose (10 patients [19%]) groups (p = 0.0007). Frequent VDI items at 12 months included hypertension (19%), diabetes (13%), atrophy and weakness (13%), osteoporosis (8%), and cataracts (8%). Logistic regression analysis revealed that GC dose at 12 months (odds ratio, 1.14; 95% confidence interval, 1.00–1.35) was a predictor for diabetes.

Conclusion

A reduced initial GC dose with rapid reduction might be required to ensure the safe treatment of elderly AAV patients.

Introduction

Treatment with high-dose glucocorticoid (GC) and immunosuppressants has greatly improved the prognosis of patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) [1, 2], but chronic damage has become a major concern in such patients. Because disease severity was reportedly related to chronic damage [3], intensive immunosuppressive treatment is required to induce the remission of AAV. On the other hand, GC is a risk factor for chronic damage as well as infectious complications [4, 5].

AAV often occurs in elderly populations, particularly in Japan [6], and aging is a strong risk factor for death and end-stage renal disease [7,8,9,10]. Due to the high incidence of chronic conditions including diabetes mellitus, osteoporosis, cataracts, and hypertension in elderly populations with AAV [11], GC-related damage might be more serious. Because many studies of AAV have excluded elderly patients, optimization of the initial GC dose and tapering speed might be required to ensure their safe treatment.

In this study, treatment-related damage was evaluated in patients with elderly-onset AAV based on safety outcome analysis using data from two nationwide prospective inception cohort studies.

Methods

Database

We used datasets from two cohort studies: RemIT-JAV (observational cohort study of remission induction therapy in Japanese patients with ANCA-associated vasculitis [UMIN000001648]) and RemIT-JAV-RPGN (observational cohort study of remission induction therapy in Japanese patients with ANCA-associated vasculitis and rapidly progressive glomerulonephritis [UMIN000005136]). Consecutive patients with newly diagnosed AAV were enrolled in RemIT-JAV between April 2009 and December 2010 from 22 tertiary care institutions or in RemIT-JAV-RPGN from April 2011 to March 2014 from 53 tertiary care institutions. The criteria for enrolment for both studies included the following: (1) diagnosis of AAV by the site investigators, (2) fulfillment of criteria for primary systemic vasculitis as proposed by the European Medicines Agency algorithm [12], and (3) starting immunosuppressive treatment based on site investigator discretion [13, 14]. The exclusion criteria were as follows: (1) age younger than 20 years, (2) serologic evidence of hepatitis B or C virus infection, and (3) a history of malignancy. Baseline data recorded for each patient included demographic information, laboratory data, Birmingham Vasculitis Activity Score (BVAS) 2003 [15], and disease severity. Disease severity was subclassified as localized, early systemic, generalized, or severe according to the European Vasculitis Study Group definition of disease severity types [16]. Patients with threatened vital organ function were classified as having generalized disease, while those with organ failure were classified as having severe disease. Detailed definitions of disease severity were described previously [17]. Patients were evaluated at 3, 6, 12, 18, and 24 months and at relapse, and the following data were collected: vital status, BVAS 2003, laboratory data, treatments, and adverse events. The Vasculitis Damage Index (VDI) score was recorded at 6, 12, and 24 months [18].

Patient selection and outcome measures

In the present study, patients with elderly-onset (≥ 75 years) AAV were enrolled. Patients for whom data about the GC dose were lacking were excluded.

The primary outcome measure was 12-month treatment-related VDI score. Treatment-related VDI was defined as in the previous report as follows: osteoporosis, diabetes, cataracts, atrophy and weakness, malignancy, gonadal failure, marrow failure, chemical cystitis, avascular necrosis, hypertension, angina/coronary artery disease, alopecia, cerebrovascular accident, myocardial infarction, and mouth ulcers [4]. Secondary outcome measures included serious infections within 6 months, 12-month total VDI score, remission, and relapse. Our definition of serious infections was based on an International Conference on Harmonization report [19]. Bacterial infections requiring intravenous antibiotic administration and opportunistic infections were considered serious infections. The diagnosis of infection was based on the attending physician’s clinical diagnosis using a comprehensive evaluation of physical findings, laboratory data, and imaging data. Remission was defined as a BVAS score of 0 on 2 consecutive occasions at least 1 month apart according to the European League Against Rheumatism (EULAR) recommendations [16]. Relapse was defined as recurrent or new-onset clinical signs and symptoms attributable to active vasculitis as we previously reported [20].

Statistical analysis

Clinical characteristics are presented as mean ± standard deviation (SD). The patients were divided into three groups according to initial GC dose: high-dose, prednisolone (PSL) ≥ 0.8 mg/kg/day; medium-dose, 0.6 ≤ PSL < 0.8 mg/kg/day; and low-dose, PSL < 0.6 mg/kg/day. Patient characteristics and outcomes were compared across the three GC dose groups. Continuous variables were compared using the Mann–Whitney U test, whereas categorical variables were compared between two groups using the Fisher exact probability test. p values < 0.05 were considered significant. Statistical significance was determined using Bonferroni correction, < 0.05/3, to adjust for multiple testing. To explore the factors related to VDI items, multiple linear regression and logistic regression analyses were performed. All statistical analyses were performed using JMP 11.2.0 software (SAS Institute Inc., Cary, NC, USA).

Results

Patient characteristics

Of 477 patients registered in the two cohort studies, 181 fulfilled the inclusion criteria. Among them, 2 were excluded because of a lack of data about the GC dose. For the analysis of VDI score, 60 patients without a 12-month score were excluded. Of those 60 excluded patients, 19 died by 12 months. The mean age (SD) of the 179 enrolled patients was 80.0 (3.8) years, 111 (62%) were female, and the baseline mean (SD) BVAS was 16.1 (6.6). Seven (4%) patients had eosinophilic granulomatosis with polyangiitis, 28 (16%) had granulomatosis with polyangiitis, 113 (63%) had microscopic polyangiitis, and 31 (17%) were unclassifiable. Myeloperoxidase–antineutrophil cytoplasmic antibody (MPO-ANCA) results were positive in 168 (94%) patients, while proteinase 3–ANCA (PR3-ANCA) results were positive in 11 (6%) patients. Concomitant cyclophosphamide (CY) was used in 54 (30%) patients, and the mean (SD) GC dose was 0.73 (0.25) mg/kg/day. Prophylaxis against Pneumocystis pneumonia was administrated in 153 of 178 (86%) patients (there was no statistical difference compared to patients aged < 75 years: 243 of 292 [83%], p = 0.43).

The patient characteristics of the three groups are summarized in Table 1. The low-dose group had a significantly higher mean age than the high-dose group. There were no significant intergroup differences in sex, disease classification, or disease severity. Mean BVAS score did not differ significantly, while the high-dose group exhibited a significantly lower mean serum creatinine level than the low-dose group.

Table 1 Patient characteristics by initial GC dose group
Full size table

Mean (SD) daily PSL doses at initial treatment in the low-, medium-, and high-dose groups were 0.47 (0.10), 0.69 (0.05), and 0.98 (0.18) mg/kg, respectively. The proportion of concomitant CY use was significantly different among groups: low-dose, 8 (13%); medium-dose, 10 (19%); and high-dose, 36 (53%); p < 0.0001.

Treatment effectiveness and safety

By 12 months, 151 (84%) patients achieved remission; of those, 17 (11%) experienced a relapse. Mean (SD) total VDI score at 12 months was 2.4 (1.8), while mean (SD) treatment-related VDI score was 0.7 (1.0). The proportions of patients with each VDI item at 12 months are shown in Fig. 1. Frequent VDI items (> 5% of enrolled patients) were as follows: hypertension (19%), diabetes (13%), atrophy and weakness (13%), osteoporosis (8%), and cataracts (8%). Serious infections within 6 months developed in 52 (29%) patients.

Fig. 1
figure 1

Frequency of treatment-related VDI items at 12 months. VDI, Vasculitis Damage Index

Full size image

There were no statistically significant intergroup differences in remission or relapse by 12 months: remission—50 (85%) of 59 patients in low-dose, 41 (79%) of 52 in medium-dose, and 60 (88%) of 68 in high-dose, respectively, p = 0.38; relapse—5 (10%) of 50 in low-dose, 5 (12%) of 41 in medium-dose, and 7 (12%) of 60 in high-dose, respectively, p = 0.93. Even limited in patients with severe form, remission and relapse were not different statistically (remission: 66% in low-dose, 63% in medium-dose, and 67% in high-dose, respectively, p = 0.98; relapse: 0%, 20%, and 13%, respectively, p = 0.46). Serious infections developed more frequently in the high-dose (n = 29 [43%]) than in the low-dose (n = 13 [22%]) or medium-dose (n = 10 [19%]) groups (p = 0.0007). Same trends were found in each dataset (RemIT-JAV group: 45% in high-dose, 13% in medium-dose, and 15% in low-dose, respectively, p = 0.04; RemIT-JAV-RPGN group: 41% in high-dose, 22% in medium-dose, and 24% in low-dose, respectively, p = 0.10).

Vasculitis Damage Index

Mean (SD) VDI scores of all patients in the RemIT-JAV and RemIT-JAV-RPGN groups were 1.7 (1.7) and 2.1 (1.6) at 6 months, and 2.0 (1.7) and 2.5 (1.8) at 12 months, respectively.

Of 121 patients with VDI scores at 12 months, total and treatment-related VDI scores at 12 months showed no statistically significant intergroup differences (total VDI score: low-dose, 2.65 ± 1.99; medium-dose, 2.40 ± 1.67; and high-dose, 2.25 ± 1.70, p = 0.57; treatment-related VDI score: low-dose, 0.91 ± 1.18; medium-dose, 0.45 ± 0.71; and high-dose, 0.77 ± 1.04, p = 0.14).

For the determination of variables associated with total and treatment-related VDI scores at 12 months, a multiple linear regression analysis was performed of the following candidate variables: sex, age, initial GC dose, initial CY usage, and initial serum creatinine level. No statistically significant variables were identified (Supplementary Table 1).

Next, we explored variables related to 5 frequent treatment-related VDI items at 12 months using logistic regression analysis including the same candidate variables. Hypertension, atrophy and weakness, osteoporosis, and cataracts were eliminated (Supplementary Table 2), while CY usage was identified as an independent predictor for a less frequent development of diabetes (Table 2, model 1).

Table 2 Risk factors for the development of diabetes at 12 months
Full size table

Because mean (SD) GC dose at 12 months was lower in patients with concomitant CY than in those without it (6.8 [3.5] vs. 9.5 [6.9] mg/day, p = 0.016), we performed a multiple linear regression analysis including GC dose at 12 months instead of concomitant CY usage; GC dose at 12 months was also identified as an independent predictor for diabetes (Table 2, model 2).

Discussion

This is the first report to evaluate damage in elderly patients with AAV. The low-dose initial GC group was older and had more severe renal impairment but less frequent concomitant CY use. The high-dose group more frequently developed serious infections. Total and treatment-related VDI scores did not differ significantly among the initial GC dose groups. GC dose at 12 months was an independent predictor for diabetes.

Our findings suggest that initial GC dose perhaps is reduced during treatment in elderly patients with AAV. Serious infections developed more frequently in the high-dose group, but remission, relapse, and VDI score were comparable to those of the other groups. Although CY dose was recommended to be reduced according to age and renal function with concern about adverse drug reactions in the EULAR recommendation for the treatment of AAV [21], the initial dose adjustment of GC was not stated, and PSL 1 mg/kg/day has traditionally been initiated since the 1970s [22]. The PEXIVAS trial reported that a reduced-dose GC regimen (initial dose, ~ 0.5 mg/kg/day) was non-inferior to the standard regimen (initial dose, ~ 1 mg/kg/day) with respect to death or end-stage renal failure in patients with severe AAV [23]. Initial GC dose and age were reportedly related to serious infection in the immunosuppressive treatment of rheumatic diseases [24,25,26]. Our previous study also showed that PSL > 0.8 mg/kg/day was a risk factor for severe infection in patients with AAV [5]. Therefore, the reduction of the initial GC dose could lead to improved safety outcomes in elderly patients.

Diabetes, atrophy and weakness, osteoporosis, and cataracts were emphasized as chronic damage in elderly AAV patients. Although the order of the frequency of treatment-related VDI items was comparable to those of the previous report for VDI for AAV patients of all ages, diabetes (13% in present study vs. 8% in the previous study), atrophy and weakness (13% vs. 6%), osteoporosis (8% vs. 4%), and cataracts (8% vs. 3%) were more frequent in the present study [27]. These items are also well-known concerns in general elderly patients, and our result indicates that AAV treatment accelerates this damage in elderly AAV patients.

A delay in the GC reduction without concomitant CY usage and renal impairment might lead to the development of diabetes. Concomitant CY usage was determined as a protective predictor for diabetes by analysis of initial treatment with patient characteristics. Our recent study also demonstrated a GC sparing effect of concomitant CY in AAV patients, as the GC dose at 12 months was lower in patients with concomitant CY than those without CY [28]. Even on multivariate analysis with the model including GC dose at 12 months instead of concomitant CY usage, GC dose at 12 months remained a statistical predictor for diabetes. Because the achievement of PSL 5–7.5 mg/day by 5 months is recommended in the EULAR guidelines, an earlier reduction of GC dose might be attempted in elderly AAV patients with renal impairment [21].

There are some limitations to this study. First, the majority of our patients were MPO-ANCA–positive. There are several differences in characteristics between patients with MPO-ANCA and those with PR3-ANCA [29, 30], and our results might not be applicable to the treatment of elderly patients with PR3-ANCA. Second, the treatment strategy was decided by each attending physician, so frail patients might have been treated conservatively, leading to underestimation of the outcomes. Nevertheless, patients with higher GC doses at 12 months had diabetes more frequently, supporting the relevance of a sufficient and early GC dose reduction in elderly patients. Third, we could not validate our exploratory results in another dataset because of insufficient sample size, so further validation study is required.

Conclusion

Rapidly reducing the initial GC dose to PSL < 0.8 mg/kg/day perhaps is required to ensure the safe treatment of elderly patients with AAV.

Availability of data and materials

The dataset analyzed in this paper is available from the corresponding author on reasonable request.

Abbreviations

AAV:

Antineutrophil cytoplasmic antibody–associated vasculitis

ANCA:

Antineutrophil cytoplasmic antibody

BVAS:

Birmingham Vasculitis Activity Score

CY:

Cyclophosphamide

EULAR:

European League Against Rheumatism

GC:

Glucocorticoid

MPO-ANCA:

Myeloperoxidase–antineutrophil cytoplasmic antibody

PR3-ANCA:

Proteinase 3–antineutrophil cytoplasmic antibody

PSL:

Prednisolone

RemIT-JAV:

Observational cohort study of remission induction therapy in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis

RemIT-JAV-RPGN:

Observational cohort study of remission induction therapy in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis and rapidly progressive glomerulonephritis

SD:

Standard deviation

VDI:

Vasculitis Damage Index

References

  1. Holle JU, Gross WL, Latza U, Nolle B, Ambrosch P, Heller M, Fertmann R, Reinhold-Keller E. Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011;63(1):257–66.

    Article  Google Scholar 

  2. Hilhorst M, Wilde B, van Paassen P, Winkens B, van Breda VP, Cohen Tervaert JW. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant. 2013;28(2):373–9.

    Article  CAS  Google Scholar 

  3. Sreih AG, Mandhadi R, Aldaghlawi F, Khan A, Irshad V, Finn K, Block JA. ANCA-associated vasculitis in Hispanic Americans: an unrecognized severity. Clin Rheumatol. 2015;34(5):943–8.

    Article  Google Scholar 

  4. Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P, Jayne D, Mahr A, Westman K, Luqmani R. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015;54(3):471–81.

    Article  CAS  Google Scholar 

  5. Watanabe-Imai K, Harigai M, Sada KE, Yamamura M, Fujii T, Dobashi H, Amano K, Ito S, Homma S, Kumagai S, et al. Clinical characteristics of and risk factors for serious infection in Japanese patients within six months of remission induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis registered in a nationwide, prospective, inception cohort study. Mod Rheumatol. 2017;27(4):646–51.

    Article  CAS  Google Scholar 

  6. Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, Hashimoto H, Nunoi H. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford). 2011;50(10):1916–20.

    Article  Google Scholar 

  7. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients. Rheumatology (Oxford). 2005;44(4):495–501.

    Article  CAS  Google Scholar 

  8. Chen M, Yu F, Zhang Y, Zhao MH. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine (Baltimore). 2008;87(4):203–9.

    Article  CAS  Google Scholar 

  9. Bomback AS, Appel GB, Radhakrishnan J, Shirazian S, Herlitz LC, Stokes B, D'Agati VD, Markowitz GS. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 2011;79(7):757–64.

    Article  Google Scholar 

  10. Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, Jayne D, Harper L, European Vasculitis Study G. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010;69(6):1036–43.

    Article  Google Scholar 

  11. Weiner M, Goh SM, Mohammad AJ, Hruskova Z, Tanna A, Bruchfeld A, Selga D, Chocova Z, Westman K, Eriksson P, et al. Outcome and treatment of elderly patients with ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2015;10(7):1128–35.

    Article  Google Scholar 

  12. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222–7.

    Article  Google Scholar 

  13. Sada KE, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, Ito S, Yamada H, Wada T, Hirahashi J, et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther. 2014;16(2):R101.

    Article  Google Scholar 

  14. Sada KE, Yamamura M, Harigai M, Fujii T, Arimura Y, Makino H. Issues associated with the Ministry of Health, Labour and Welfare diagnostic criteria for antineutrophil cytoplasmic antibody-associated vasculitides: reclassification of patients in the prospective cohort study of Remission Induction Therapy in Japanese patients with ANCA-associated vasculitides according to the MHLW criteria. Mod Rheumatol. 2015;25(4):657–9.

    Article  Google Scholar 

  15. Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, Westman K, Luqmani R. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;66(3):283–92.

    PubMed  Google Scholar 

  16. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66(5):605–17.

    Article  CAS  Google Scholar 

  17. Sada KE, Harigai M, Amano K, Atsumi T, Fujimoto S, Yuzawa Y, Takasaki Y, Banno S, Sugihara T, Kobayashi M, et al. Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Mod Rheumatol. 2016;26(5):730–7.

    Article  CAS  Google Scholar 

  18. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, Adu D. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40(2):371–80.

    Article  CAS  Google Scholar 

  19. Vijayananthan A, Nawawi O. The importance of Good Clinical Practice guidelines and its role in clinical trials. Biomed Imaging Interv J. 2008;4(1):e5.

    Article  CAS  Google Scholar 

  20. Hara A, Wada T, Sada KE, Amano K, Dobashi H, Harigai M, Takasaki Y, Yamada H, Hasegawa H, Hayashi T, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis in Japan: a nationwide, prospective cohort study. J Rheumatol. 2018;45(4):521–8.

    Article  CAS  Google Scholar 

  21. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583–94.

    Article  CAS  Google Scholar 

  22. Novack SN, Pearson CM. Cyclophosphamide therapy in Wegener’s granulomatosis. N Engl J Med. 1971;284(17):938–42.

    Article  CAS  Google Scholar 

  23. Walsh M, Merkel PA, Peh CA, Szpirt WM, Puechal X, Fujimoto S, Hawley CM, Khalidi N, Flossmann O, Wald R, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622–31.

    Article  CAS  Google Scholar 

  24. Wilson JC, Sarsour K, Gale S, Petho-Schramm A, Jick SS, Meier CR. Incidence and risk of glucocorticoid-associated adverse effects in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(4):498–511.

    Article  Google Scholar 

  25. Noel V, Lortholary O, Casassus P, Cohen P, Genereau T, Andre MH, Mouthon L, Guillevin L. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis. 2001;60(12):1141–4.

    Article  CAS  Google Scholar 

  26. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(4):R109.

    Article  Google Scholar 

  27. Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P, Jayne D, Mahr A, Westman K, Luqmani R. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74(1):177–84.

    Article  Google Scholar 

  28. Watanabe H, Sada KE, Matsumoto Y, Harigai M, Amano K, Fujimoto S, Dobashi H, Yuzawa Y, Yamagata K, Muso E, et al. Rationale of concomitant cyclophosphamide for remission-induction in patients with antineutrophil cytoplasmic antibody-associated vasculitis: a propensity score-matched analysis of two nationwide prospective cohort studies. Mod Rheumatol. 2020:1–9. https://doi.org/10.1080/14397595.2019.1707997.

  29. Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, Nachman PH, Jennette JC, Falk RJ. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452–62.

    Article  CAS  Google Scholar 

  30. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214–23.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank all the medical staff members in our department.

Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS) and Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan—in addition to the authors, the following investigators and institutions participated in this study: Department of Nephrology, Faculty of Medicine, University of Tsukuba (Joichi Usui); Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University (Tatsuya Atsumi); Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital (Takahiko Sugihara); Department of Nephrology, Internal Medicine, Nagoya University Graduate School of Medicine (Seiichi Matsuo); Department of Human Resource Development of Dialysis Therapy for Kidney Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences (Hitoshi Sugiyama); Faculty of Health Sciences, Hokkaido University (Akihiro Ishizu); Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University (Takao Fujii); Department of Pathology, Keio University School of Medicine (Yasunori Okada); Department of Respiratory Medicine, Toho University Omori Medical Center (Sakae Homma); Department of Nephrology, Internal Medicine, Nagoya University Graduate School of Medicine (Naotake Tsuboi); Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine (Shunichi Kumagai); Department of Nephrology and Dialysis, Kitano Hospital, Tazuke Kofukai Medical Research Institute (Eri Muso); Department of Rheumatology, Shimane University Faculty of Medicine (Yohko Murakawa); Division of Rheumatology, Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Science (Shogo Banno); Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine (Hitoshi Hasegawa); Division of Nephrology, Department of Internal Medicine, Jichi Medical University (Wako Yumura); Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine (Hiroaki Matsubara); Division of Nephrology, Tokyo Medical University Hachioji Medical Center (Masaharu Yoshida); Department of Dermatology, Kitasato University School of Medicine (Kensei Katsuoka); Division of Immunology and Rheumatology, Department of Internal Medicine 3, Hamamatsu University School of Medicine (Noriyoshi Ogawa); Department of Hematology, Oncology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine (Atsushi Komatsuda); Department of Rheumatology, Niigata Rheumatic Center (Satoshi Ito); Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences (Atsushi Kawakami); Department of Nephrology, Iwate Prefectural Central Hospital (Izaya Nakaya); Division of Nephrology and Rheumatology, Department of Internal Medicine, Fukuoka University School of Medicine (Takao Saito); Shimane University, Faculty of Medicine, Division of Nephrology (Takafumi Ito); Department of Hemodialysis and Apheresis, Yokohama City University Medical Center (Nobuhito Hirawa); Center for Rheumatology, Okayama Saiseikai General Hospital (Masahiro Yamamura); Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University (Masaaki Nakano); Department of Medicine, Kidney Center, Tokyo Women’s Medical University (Kosaku Nitta); Division of Nephrology and Hypertension, Kashiwa Hospital, Jikei University (Makoto Ogura); Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences (Taio Naniwa); Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine (Shoichi Ozaki); Department of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo (Junichi Hirahashi); Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine (Tatsuo Hosoya); Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University (Takashi Wada); Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine (Satoshi Horikoshi); Institute of Rheumatology, Tokyo Women’s Medical University (Yasushi Kawaguchi); Division of Clinical Immunology, Graduate School of Comprehensive Human Sciences, University of Tsukuba (Taichi Hayashi); Department of Nephrology, Hypertension, Diabetology, Endocrinology and Metabolic, Fukushima Medical University (Tsuyoshi Watanabe); Department of Nephrology, Japanese Red Cross Nagoya Daini Hospital (Daijo Inaguma); Department of Integrated Therapy for Chronic Kidney Disease, Kyushu University (Kazuhiko Tsuruya); Niigata Prefectural Shibata Hospital (Noriyuki Homma); Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine (Tsutomu Takeuchi); Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University (Naoki Nakagawa); Kurobe City Hospital (Shinichi Takeda); National Fukuoka Higashi Medical Center (Ritsuko Katafuchi); Division of Nephrology, Department of Medicine, Faculty of Medical Sciences, University of Fukui (Masayuki Iwano); and Tokyo Medical University Ibaraki Medical Center (Masaki Kobayashi).

Funding

This work was supported by grants from the Ministry of Health, Labour, and Welfare, Japan (nannti-ippann-004 and nannti-ippann-018), and the Japan Agency for Medical Research and Development (JP17ek0109104, JP17ek0109121, and JP18ek0109360).

Author information

Authors and Affiliations

  1. Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, 783-8505, Japan

    Ken-Ei Sada, Keiji Ohashi, Yosuke Asano, Keigo Hayashi, Michiko Morishita, Haruki Watanabe & Yoshinori Matsumoto

  2. Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

    Ken-Ei Sada

  3. Department of Hemovascular Medicine and Artificial Organs, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

    Shouichi Fujimoto

  4. Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

    Yoshinari Takasaki

  5. Department of Nephrology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan

    Kunihiro Yamagata

  6. Department of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan

    Shogo Banno

  7. Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan

    Hiroaki Dobashi

  8. Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan

    Koichi Amano

  9. Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan

    Masayoshi Harigai

  10. Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan

    Yoshihiro Arimura

  11. Kichijoji Asahi Hospital, Tokyo, Japan

    Yoshihiro Arimura

  12. Okayama University, Okayama, Japan

    Hirofumi Makino

Authors
  1. Ken-Ei Sada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keiji Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yosuke Asano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keigo Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michiko Morishita
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Haruki Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshinori Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shouichi Fujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoshinari Takasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kunihiro Yamagata
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shogo Banno
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hiroaki Dobashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Koichi Amano
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Masayoshi Harigai
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Yoshihiro Arimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hirofumi Makino
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS) and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan

  • Joichi Usui
  • , Tatsuya Atsumi
  • , Takahiko Sugihara
  • , Seiichi Matsuo
  • , Hitoshi Sugiyama
  • , Akihiro Ishizu
  • , Takao Fujii
  • , Yasunori Okada
  • , Sakae Homma
  • , Naotake Tsuboi
  • , Shunichi Kumagai
  • , Eri Muso
  • , Yohko Murakawa
  • , Shogo Banno
  • , Hitoshi Hasegawa
  • , Wako Yumura
  • , Hiroaki Matsubara
  • , Masaharu Yoshida
  • , Kensei Katsuoka
  • , Noriyoshi Ogawa
  • , Atsushi Komatsuda
  • , Satoshi Ito
  • , Atsushi Kawakami
  • , Izaya Nakaya
  • , Takao Saito
  • , Takafumi Ito
  • , Nobuhito Hirawa
  • , Masahiro Yamamura
  • , Masaaki Nakano
  • , Kosaku Nitta
  • , Makoto Ogura
  • , Taio Naniwa
  • , Shoichi Ozaki
  • , Junichi Hirahashi
  • , Tatsuo Hosoya
  • , Takashi Wada
  • , Satoshi Horikoshi
  • , Yasushi Kawaguchi
  • , Taichi Hayashi
  • , Tsuyoshi Watanabe
  • , Daijo Inaguma
  • , Kazuhiko Tsuruya
  • , Noriyuki Homma
  • , Tsutomu Takeuchi
  • , Naoki Nakagawa
  • , Shinichi Takeda
  • , Ritsuko Katafuchi
  • , Masayuki Iwano
  •  & Masaki Kobayashi

Contributions

KS and KO were responsible for the conception and design, analysis, and manuscript writing. YA, KH, MM, HW, and YM were responsible for the data collection and critical revision. SF, YT, KY, SB, HD, and KA were responsible for the data collection and interpretation. MH, YA, and HM were responsible for the data collection, interpretation, and critical revision. YA was responsible for the conception and design, data collection and analysis, and critical revision. HM was responsible for the data analysis, interpretation, and critical revision. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Ken-Ei Sada.

Ethics declarations

Ethics approval and consent to participate

This study was conducted in accordance with the Declaration of Helsinki and the ethical guidelines for epidemiological research in Japan. This study was approved by the Ethics Committee of Okayama University Hospital and Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences (approval number, Ken1904-023). Informed consent and permission to publish their data were obtained from all participants.

Consent for publication

No individual person’s data were presented in any form in this study, and therefore, no consent to publish is required.

Competing interests

KS received speaker’s fee from Astra Zeneca K.K. KA received speaker’s fee from Chugai Pharmaceutical Co. MH has received unrestricted research grants from AbbVie Japan GK; Ayumi Pharmaceutical Co.; Bristol Myers Squibb Co., Ltd.; Eisai Co., Ltd.; Nippon Kayaku Co., Ltd.; Mitsubishi Tanabe Pharma Co.; and Teijin Pharma Ltd. MH has received speaker’s fee from Boehringer-Ingelheim; Kissei Pharmaceutical Co., Ltd.; Eli Lilly Japan K.K.; and Chugai Pharmaceutical Co., Ltd. MH is a consultant for AbbVie; Boehringer-Ingelheim; Kissei Pharmaceutical Co., Ltd.; and Teijin Pharma. HM is a consultant for AbbVie, Boehringer-Ingelheim, and Teijin.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1: Table S1.

Risk factors for total and treatment-related VDI. Table S2. Risk factors for hypertension, atrophy and weakness, cataract, and osteoporosis.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sada, KE., Ohashi, K., Asano, Y. et al. Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies. Arthritis Res Ther 22, 236 (2020). https://doi.org/10.1186/s13075-020-02341-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13075-020-02341-6

Keywords

  • ANCA-associated vasculitis
  • Chronic damage
  • Elderly patients
  • Glucocorticoids

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us